8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                  _____________

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported):  October 7, 2004


                               Immunomedics, Inc.
- --------------------------------------------------------------------------------
             (Exact Name of Registrant as Specified in Its Charter)


            Delaware                  000-12104             61-1009366
- --------------------------------------------------------------------------------
  (State or Other Jurisdiction       (Commission        (I.R.S.  Employer
        of Incorporation)            File Number)       Identification No.)


300 American Road, Morris Plains, New Jersey                   07950
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices)                    (Zip Code)


Registrant's telephone number, including area code:           (973) 605-8200
- --------------------------------------------------------------------------------

                                 Not Applicable
- --------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)

      Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

            |_| Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)

            |_| Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)

            |_| Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))

            |_| Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))



Item 5.02.  Departure  of  Directors  or  Principal   Officers;   Election  of
            Directors; Appointment of Principal Officers.

            (d) On October 12, 2004, Immunomedics, Inc. (the "Company") issued a
press release announcing that Brian A. Markison has been appointed to the
Company's Board of Directors. Mr. Markison was appointed by the Board of
Directors on October 7, 2004, and was named as a member of the Company's
Governance and Nominating Committee and Research and Development Committee. Mr.
Markison will stand for election together with the Company's other directors at
the Company's 2004 annual meeting of stockholders. A copy of the press release
is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference.

Item 9.01.  Financial Statements and Exhibits.

            (c) Exhibits:

                  99.1  Press Release, dated October 12, 2004



                                   SIGNATURES

            Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.

Date:  October 13, 2004                IMMUNOMEDICS, INC.



                                       By:       /s/ Gerard G. Gorman
                                          --------------------------------------
                                          Name:  Gerard G. Gorman
                                          Title: Vice President, Finance, and
                                                 Chief Financial Officer





                                  EXHIBIT INDEX
                                  -------------

    EXHIBIT NUMBER                                     DESCRIPTION
    --------------                                     -----------

         99.1                              Press Release, dated October 12, 2004

EX-99.1

                                                                    EXHIBIT 99.1

                   IMMUNOMEDICS NAMES BRIAN A. MARKISON TO
                              BOARD OF DIRECTORS

Morris Plains, NJ, October 12, 2004 - Immunomedics, Inc. (Nasdaq: IMMU) today
announced that Brian A. Markison has been appointed to the Company's Board of
Directors. Mr. Markison is the President and Chief Executive Officer, and a
member of the Board of Directors, of King Pharmaceuticals, Inc. (NYSE: KG). Mr.
Markison has a distinguished career of over 22 years in sales, marketing,
strategic planning and general management, both domestically and
internationally, in the pharmaceuticals industry.

Prior to joining King Pharmaceuticals, he was the President of Oncology,
Virology and Oncology Therapeutics Network at Bristol-Myers Squibb, where he
held a number of key leadership roles throughout his career. The Board of
Directors will recommend the election of Mr. Markison in the 2004 proxy, which
will be distributed at the end of October.

Mr. Markison stated: "I am excited about the prospects for Immunomedics, and
hope to leverage my oncology and immunology experience to assist the Company
with its strategy for growth." Dr. David M. Goldenberg, Chairman of the Board
and founder of the Company, remarked: "We are delighted to have such an
experienced and capable pharmaceutical executive join us. His commercial
development and licensing experience are of particular value to us as we advance
our therapeutic product candidates and seek partnering opportunities for their
commercialization."

Immunomedics, Inc. is a biopharmaceutical company focused on the development,
manufacture and commercialization of diagnostic imaging and therapeutic products
for the detection and treatment of cancer and other serious diseases. Integral
to these products are highly specific monoclonal antibodies and antibody
fragments designed to deliver radioisotopes and chemotherapeutic agents to
tumors and other sites of disease. Immunomedics has therapeutic product
candidates in clinical development and has two marketed diagnostic imaging
products. Our most advanced therapeutic product candidate is epratuzumab, for
which certain Phase II clinical trials for the treatment of non-Hodgkin's
lymphoma have already been completed.

This release, in addition to historical information, contains forward-looking
statements made pursuant to the Private Securities Litigation Reform Act of
1995. Such statements, including statements regarding clinical trials, involve
significant risks and uncertainties and actual results could differ materially
from those expressed or implied herein. Factors that could cause such
differences include, but are not limited to, risks associated with new product
development (including clinical trials outcome and regulatory
requirements/actions), competitive risks to marketed products and availability
of financing and other sources of capital, as well as the risks discussed in the
Company's Annual Report on Form 10-K for the year June 30, 2004. The Company is
not under any obligation, and the Company expressly disclaims any obligation, to
update or alter any forward-looking statements, whether as a result of new
information, future events or otherwise. Company Contact: Chau Cheng, Associate
Director, Investor Relations & Business Analysis, (973) 605-8200, extension 123.
Visit the Company's web site at (http://www.immunomedics.com).